Global investment firm The Carlyle Group is acquiring 20% in the Piramal group's pharma business for around $490m, setting the stage for the Indian group to pursue an ambitious growth strategy including buyouts both on home turf and internationally.
The transaction ends months of build-up around an imminent deal involving Piramal, which was also speculated to have had private...





